Association of rs780094 in GCKR with Metabolic Traits and Incident Diabetes and Cardiovascular Disease: The ARIC Study by Bi, Mark et al.
Association of rs780094 in GCKR with Metabolic Traits
and Incident Diabetes and Cardiovascular Disease:
The ARIC Study
Mark Bi
1, Wen Hong Linda Kao
2, Eric Boerwinkle
3, Ron C. Hoogeveen
4, Laura J. Rasmussen-Torvik
5,
Brad C. Astor
2, Kari E. North
6, Josef Coresh
2, Anna Ko ¨ttgen
2,7*
1School of Biological Sciences, University of Nebraska at Lincoln, Lincoln, Nebraska, United States of America, 2Department of Epidemiology, Johns Hopkins Bloomberg
School of Public Health, Baltimore, Maryland, United States of America, 3Human Genetics Center and Division of Epidemiology, University of Texas Health Science Center
at Houston, Houston, Texas, United States of America, 4Department of Medicine, Baylor College of Medicine, Houston, Texas, United States of America, 5Division of
Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, United States of America, 6Department of Epidemiology and Carolina Center for
Genome Sciences, University of North Carolina, Chapel Hill, North Carolina, United States of America, 7Renal Division, University Hospital Freiburg, Freiburg, Germany
Abstract
Objective: The minor T-allele of rs780094 in the glucokinase regulator gene (GCKR) associates with a number of metabolic
traits including higher triglyceride levels and improved glycemic regulation in study populations of mostly European
ancestry. Using data from the Atherosclerosis Risk in Communities (ARIC) Study, we sought to replicate these findings,
examine them in a large population-based sample of African American study participants, and to investigate independent
associations with other metabolic traits in order to determine if variation in GKCR contributes to their observed clustering. In
addition, we examined the association of rs780094 with incident diabetes, coronary heart disease (CHD), and stroke over up
mean follow-up times of 8, 15, and 15 years, respectively.
Research Design and Methods: Race-stratified analyses were conducted among 10,929 white and 3,960 black participants
aged 45–64 at baseline assuming an additive genetic model and using linear and logistic regression and Cox proportional
hazards models.
Results: Previous findings replicated among white participants in multivariable adjusted models: the T-allele of rs780094
was associated with lower fasting glucose (p=10
27) and insulin levels (p=10
26), lower insulin resistance (HOMA-IR,
p=10
29), less prevalent diabetes (p=10
26), and higher CRP (p=10
28), 2-h postprandial glucose (OGTT, p=10
26), and
triglyceride levels (p=10
231). Moreover, the T-allele was independently associated with higher HDL cholesterol levels
(p=0.022), metabolic syndrome prevalence (p=0.043), and lower beta-cell function measured as HOMA-B (p=0.011).
Among black participants, the T-allele was associated only with higher triglyceride levels (p=0.004) and lower insulin levels
(p=0.002) and HOMA-IR (p=0.013). Prospectively, the T-allele was associated with reduced incidence of diabetes (p=10
24)
among white participants, but not with incidence of CHD or stroke.
Conclusions: Our findings indicate rs780094 has independent associations with multiple metabolic traits as well as incident
diabetes, but not incident CHD or stroke. The magnitude of association between the SNP and most traits was of lower
magnitude among African American compared to white participants.
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Introduction
Metabolic traits that are risk factors for cardiovascular disease
(CVD) commonly occur together [1] and in a specific
combination are known as metabolic syndrome. Metabolic
syndrome has been linked to increased all-cause mortality,
CVD, and diabetes mellitus (DM)[1–4]. While the individual
metabolic traits have heritable components, it is less clear
whether such clustering has a common biologic basis [4,5].
Genome-wide association studies (GWAS) have discovered
susceptibility loci for some of the individual components such
as glucose and lipid levels [6–8] (and http://www.genome.gov/
GWAstudies/). Genetic loci associated with serum levels of
biomarkers related to the metabolic syndrome such as C-reactive
protein (CRP) have also been identified[9]. In light of the
clustering of metabolic risk factors, however, it is of particular
interest to investigate genetic loci that have demonstrated
association with multiple metabolic traits.
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glucokinase regulator protein (GKRP), which regulates glycolysis
primarily in liver hepatocytes but is also found in small quantities
in pancreatic beta cells [10,11]. Common variants in GCKR, most
often the minor T-allele of the common single nucleotide
polymorphism (SNP) rs780094, have been reported by multiple
candidate gene and GWA studies to be associated with decreased
fasting glucose[12–19] and insulin levels [12,16,18], lower insulin
resistance[12,15–18,20], and decreased prevalence of type 2
diabetes [12,15,16,18]. At the same time, the T allele has also
been found to be associated with increased serum triglyce-
ride[5,12,15–18,21–29], CRP[9,17,29], and 2 hour OGTT glu-
cose levels[12,30]. Some studies have also found evidence of an
association with beta cell function as measured by HOMA-B
[12,25] and HDL cholesterol concentration[17,26], although
these associations have not been observed in all studies
[13,15,18,21,23,24,27,29]. Despite its association with multiple
metabolic risk factors, studies have observed no association with
cardiovascular disease[17,21,27,31,32].
To date, most of these studies have been conducted in
populations of European[5,9,12,15,16,18–21,23,24,26,27,29–33]
and Asian ancestry[13,14,25,34]. However, it is of interest to study
metabolic risk factors in populations with particularly high
prevalence of diabetes and the metabolic syndrome, including
Hispanics, Native Americans, and African Americans. Only one
study thus far has included a population of African ancestry, where
an association of rs780094 with plasma triglyceride levels but not
fasting glucose levels was observed[17].
We therefore studied the association of rs780094 with metabolic
traits in 10,929 self-reported white and 3,960 black participants of
the Atherosclerosis Risk in Communities (ARIC) Study with the
following objectives: (1) to replicate the previously observed
associations in white participants in a large population-based
study sample; (2) to explore these associations in black study
participants; (3) to characterize the association of rs780094 with
additional metabolic traits, including waist circumference, systolic
blood pressure, HDL cholesterol concentration, homeostasis
model assessment of beta-cell function (HOMA-B), and metabolic
syndrome prevalence; and (4) to examine its prospective
association with incident diabetes, coronary heart disease
(CHD), and stroke.
Methods
Study Population
The ARIC Study is a prospective, population-based study
investigating the etiology and epidemiology of atherosclerosis.
From 1987 to 1989, 15,792 adults aged 45–64 years old were
recruited by probability sampling from 4 US locations. All
participants gave written informed consent, and the study was
approved by the local Research Ethics Committees of the four
ARIC study centers (University of Minnesota, Minneapolis;
University of Mississippi, Jackson; University of North Carolina,
Chapel Hill; Johns Hopkins University, Baltimore). Participants
underwent interviews and examinations at baseline and roughly
every 3 years afterwards for a total of 4 study visits. Annual follow-
up using telephone surveys and information collected from death
certificates and hospital discharge records is ongoing. A complete
description of the ARIC Study is available elsewhere [35].
For the current study, participants were excluded for the
following reasons: did not self-identify as white or black (n=48),
no genotyping consent (n=45), or missing genotype (n=810).
After exclusions, a total of 3,960 black and 10,929 white
participants remained and were included in univariate analyses.
Multivariate analyses were conducted separately among 10,601
white and 3,513 black participants with complete outcome and
covariate information. Subsets of both samples were used in
analyses of outcomes only measured at study visit 4 (n=7,703 [2h-
OGTT] and n=8,131 [CRP] for white participants; n=1,450
[2h-OGTT] and n=2,123 [CRP] for black participants).
Genotyping
rs780094 was genotyped at the central ARIC DNA laboratory
using the TaqMan Assay-by-Design system (Applied Biosystems;
Foster City, CA). Call rate was 93.3% in black participants and
95.5% in white participants. Genotype distributions conformed to
expectations under Hardy-Weinberg Equilibrium (p-exact .0.2
for each race). Genotyping in a set of 750 blind duplicates showed
good reproducibility (kappa coefficient 0.98).
Study Outcomes
Primary cross-sectional outcomes were traits previously ob-
served to be associated with rs780094, including serum fasting
glucose, fasting insulin, HOMA-IR, triglycerides, DM, and CRP.
We further examined additional Adult Treatment Panel III (ATP
III) criteria of the metabolic syndrome (systolic blood pressure,
HDL cholesterol, and waist circumference)[2]. Secondary cross-
sectional outcomes were postprandial glucose measured by an
oral-glucose tolerance test (OGTT), metabolic syndrome, and
HOMA-B. Baseline measurements were used for all outcomes
except those only available from the 4
th visit (CRP and post-
OGTT glucose). Diabetes was defined as a fasting serum glucose
concentration of $126 mg/dl after $8 hours of fasting, $
200 mg/dl after ,8 hours of fasting, self-reported physician
diagnosis, or current intake of diabetes medication. Metabolic
syndrome was defined as fulfillment of three or more ATP III
criteria for the metabolic syndrome (waist circumference $102 cm
(men) or $88 cm (women), triglyceride levels $150 mg/dl, HDL
cholesterol ,40 (men) or ,50 mg/dl (women), blood pressure
$130/85 mm Hg, fasting glucose $100 mg/dl).
The primary prospective outcome was incident DM[36].
Secondary prospective outcomes were incident stroke and incident
CHD defined as myocardial infarction (MI), fatal CHD, silent MI
from EKG, or cardiac revascularization procedure[37,38].
Demographic and Clinical Measurements
Race, age, sex and smoking status were self-reported at study
visits. Current medication usage was self-reported and validated by
inspection of containers. Blood pressure was measured using a
Table 1. Distribution of rs780094 in 3,960 Black and 10,929
White Atherosclerosis Risk in Communities Study Participants.
Black White
Genotypes
CC 67.9 (2,690) 36.3 (3,970)
CT 28.6 (1,134) 48.0 (5,245)
TT 3.4 (136) 15.7 (1,714)
Alleles
C 82.2 60.3
T 17.8 39.7
Note: Values expressed as percent (count). Exact p-values for Hardy-Weinberg
Equilibrium were 0.22 for white and 0.78 for black participants.
doi:10.1371/journal.pone.0011690.t001
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Genotype.
n CC CT TT P-trend
Male (%) 10,929 46.9 46.9 47.8 0.586
Age (yr) 10,929 54.3 54.3 54.5 0.244
BMI (kg/m
2) 10,922 27.065.0 27.064.8 27.064.9 0.788
Current smoker (%) 10,922 24.2 25.4 24.5 0.564
Current drinker (%) 10,913 64.8 64.4 64.3 0.677
Fasting glucose (mg/dl) 10,683 105.3629.9 105.2629.0 102.2625.9 0.002
Diabetes mellitus (%) 10,911 9.1 9.8 6.8 0.057
2 hr post-OGTT glucose (mg/dl) 7,129 137.1654.3 137.9652.8 142.5651.9 0.009
Insulin (pmol/l) 10,924 88.96155 88.36161 75.3670 0.007
HOMA-IR 10,683 3.4665.2 3.4766.3 2.9264.0 0.006
HOMA-B 10,683 113.86372 105.3686 103.7670 0.077
Triglycerides (mmol/l) 10,914 1.4460.9 1.5961.1 1.7061.2 5.2610
222
HDL cholesterol (mg/dl) 10,914 51.0616.9 50.1616.8 50.6616.6 0.129
Systolic blood pressure (mmHg) 10,924 118.3616.9 118.3616.8 119.4617.7 0.071
Waist circumference (cm) 10,919 96.1613.7 96.3613.2 96.4613.3 0.431
C-reactive protein (mg/l) 8,370 3.6365.0 4.2766.6 4.6567.3 3.1610
28
Metabolic syndrome (%) 10,878 36.4 39.0 39.2 0.016
Note: Data are mean6SD for quantitative variables and percentages for categorical variables. Sample sizes are the number of participants with non-missing information
for the respective variable out of 10,929 genotyped individuals (3,970 CC, 5,245 CT, 1,714 TT). All measurements are from baseline with the exceptions of 2 hr post-OGTT
glucose and C-reactive protein, which were only measured at the 4
th visit. P values given for association with rs780094 in linear regression for quantitative traits and
logistic regression for qualitative traits.
doi:10.1371/journal.pone.0011690.t002
Table 3. Adjusted Associations between rs780094 and Study Outcomes in White Atherosclerosis Risk in Communities Study
Participants.
Model 1* Model 2*
Quantitative traits Effect/T allele ± SE P Effect/T allele ± SE P
Triglycerides (mmol/l) +0.1360.01 2.9610
221 +0.1660.01 2.4610
231
Fasting glucose (mg/dl) 21.3960.4 0.001 21.9360.4 2.3610
27
Fasting insulin (pmol/l) 25.0761.4 2.9610
24 26.2961.3 1.9610
26
HOMA-IR 20.2460.1 0.002 20.4560.1 2.2610
29
HOMA-B 26.1463.3 0.063 28.3663.3 0.011
Waist circumference (cm) +0.0660.2 0.747 +0.0160.2 0.940
HDL cholesterol (mg/dl) 20.2160.2 0.317 +0.4360.2 0.022
Systolic blood pressure (mmHg) +0.3960.2 0.090 +0.3060.2 0.188
C-reactive protein (mg/l) +0.5360.1 7.3610
28 +0.5660.1 1.6610
28
2 hr post-OGTT glucose (mg/dl) +1.9960.9 0.025 +3.0660.7 2.8610
26
Categorical traits OR/T allele (95% CI) P OR/T allele (95% CI) P
Diabetes mellitus 0.89 (0.80–0.98) 0.019 0.78 (0.71–0.87) 5.2610
26
Metabolic syndrome 1.06 (1.00–1.12) 0.043 1.17 (1.10–1.25) 1.5610
26
Incident events HR/T allele (95% CI) P HR/T allele (95% CI) P
Diabetes mellitus 0.89 (0.81–0.98) 0.014 0.85 (0.77–0.93) 4.6610
24
Coronary heart disease 0.97 (0.91–1.04) 0.422 0.98 (0.91–1.05) 0.523
Stroke 0.94 (0.82–1.08) 0.363 0.96 (0.83–1.11) 0.570
*Note: Model 1 adjusted for age, sex, study center; model 2 adjusted for age, sex, study center, fasting glucose, fasting insulin, triglycerides. Metabolic syndrome was not adjusted
for glucose and triglycerides in model 2. HOMA-IR, HOMA-B, and DM not adjusted for fasting glucose and insulin in model 2. All cross-sectional associations evaluated using
baseline measurements (n=10,601), except for 2 hr post-OGTT glucose (n=7,073) and C-reactive protein (n=8,131), which were only measured at visit 4. 935 participants out of
9,230 developed DM over mean follow-up of 8 years; 1,705 out of 10,600 developed CHD and 418 out of 10,600 experienced a stroke over mean follow-up of 15 years.
doi:10.1371/journal.pone.0011690.t003
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the 2
nd and 3
rd reading. Blood samples were drawn, frozen at
270uC, and shipped to ARIC laboratories for storage and testing.
Fasting serum glucose levels were measured using the hexokinase–
glucose-6-phosphate dehydrogenase method, plasma triglycerides
by an enzymatic method, plasma HDL cholesterol by dextran-
magnesium precipitation and serum uric acid by uricase
oxidation[39]. Serum insulin was determined using radioimmu-
noassay at baseline and an enzyme-linked immunosorbent assay
(Boehringer Mannheim Corporation, Mannheim, Germany) at
visit 4.
At visit 4 only, a standard 75 g OGTT was administered to
participants not taking diabetes medication. Serum high-sensitivity
C-reactive protein (hsCRP) was determined using an immuno-
turbidimetric assay on a Siemens BNII analyzer (Dade Behring,
Deerfield, Ill).
A complete description of ARIC protocols is available from the
ARIC operations manual[39].
Statistical Analyses
Race-stratified analyses were conducted assuming an additive
genetic model based on previous results[16,18]. Cross-sectional
outcomes were tested for association with rs780094 using simple
and multivariable-adjusted linear and logistic regression as
applicable. Incident outcomes were tested using multivariable-
adjusted Cox proportional hazards models.
Univariate regression models were first used to replicate
previously described associations. Two multivariate models were
explored: (1) adjusted for age, sex, and study center; (2) further
adjusted for fasting glucose, insulin, and triglyceride levels. Fasting
glucose, insulin, and triglyceride levels were selected on the basis of
their consistently replicated association with rs780094. A trait was
excluded as a covariate when being evaluated as an outcome.
Covariate measurements were always used from the same visit as
measurements of the tested outcome. Because DM was diagnosed
based on glucose levels, and HOMA-IR and HOMA-B are
functions of fasting glucose and insulin, these traits were not
adjusted for each other. As fasting glucose and triglyceride levels
are used to define the presence of the metabolic syndrome,
associations with metabolic syndrome were not adjusted for these
two parameters.
Sensitivity analyses were conducted using a sub-sample of
participants who did not have diabetes and reported taking no
lipid-lowering medications at baseline. Additional sensitivity
analyses were also conducted using the means of repeated
measurements from different study visits.
Prospective analyses were conducted accordingly; baseline
measurements were used for covariates.
Since this rs780094 is an extensively studied candidate SNP, a
threshold of p=0.05 was used to indicate statistical significance.
Additionally, as the activity of the glucokinase regulator protein
is enhanced by fructose-6-phosphate but inhibited by fructose-1-
phosphate[10], we tested for an interaction between rs780094 and
total fructose intake in associations with glucose, triglyceride, and
insulin levels.
All analyses were performed using Stata version 10.0 (Stata-
Corp, College Station, TX).
Results
The frequency of the rs780094 T-allele was 39.7% among white
participants and 17.8% among black participants. Genotype and
allele distributions are shown in Table 1.
Study sample characteristics of white participants by rs780094
genotype are presented in Table 2. Previously observed associa-
tions of rs780094 and metabolic traits reached statistical
significance among white participants in univariate analyses: each
additional copy of the T-allele was associated with higher
triglyceride (p=5610
222), CRP (p=3610
28), and post-OGTT
glucose levels (p=0.009), higher prevalence of the metabolic
syndrome (p=0.016), and with lower fasting glucose (p=0.002),
fasting insulin (p=0.007) and HOMA-IR (p=0.006). There was a
trend towards lower DM prevalence (p=0.057). Demographic
characteristics, including age, sex, drinking and smoking status,
and BMI did not differ with respect to genotype.
Results of multivariable adjusted analyses in white participants
are shown in Table 3. Adjusting for age, sex, and study center
(model 1), all previously reported associations (fasting glucose,
fasting insulin, HOMA-IR, post-OGTT glucose, triglycerides,
DM, and CRP) were confirmed. A trend towards an association of
the T allele with lower HOMA-B (p=0.063) was also observed;
the association with metabolic syndrome was nominally significant
(p=0.043). Additionally, when the study sample was dichotomized
by fructose intake at the median, the association of rs780094 with
triglyceride, glucose, and insulin levels appeared to be of greater
magnitude per T allele among individuals with higher fructose
intake. However, the differences were not statistically significant
(all p-interaction .0.13).
To evaluate the individual contribution of these traits, we
included fasting glucose, insulin, and triglyceride levels as additional
covariates (model 2, Table 3). Most significant associations were
Table 4. Distribution of Study Traits in 3,960 Black
Atherosclerosis Risk in Communities Study Participants.
n CC CT TT P
Male (%) 3,960 38.8 37.2 36.0 0.293
Age (yr) 3,960 53.5 53.5 52.9 0.574
BMI (kg/m
2) 3,951 29.766.2 29.466.1 29.266.6 0.058
Current smoker (%) 3,952 30.1 28.7 36.0 0.807
Current drinker (%) 3,922 32.4 32.6 30.8 0.788
Fasting glucose (mg/dl) 3,590 113.3645.3 110.6645.1 115.7652.3 0.390
Diabetes mellitus (%) 3,878 20.1 17.7 22.6 0.367
2 hr post-OGTT glucose
(mg/dl)
1,465 141.5659.3 144.1659.9 150.6673.8 0.255
Insulin (pmol/l) 3,875 150.56299 127.56254 183.26697 0.381
HOMA-IR 3,590 5.74616.1 4.5967.1 4.4666.1 0.023
HOMA-B 3,590 132.26783 143.26344 117.7675 0.845
Triglycerides (mmol/l) 3,819 1.2860.9 1.3161.0 1.4461.3 0.050
HDL cholesterol (mg/dl) 3,818 54.6617.5 55.5617.4 55.6618.0 0.120
Systolic blood pressure
(mmHg)
3,957 128.7621.2 128.2621.6 129.3620.9 0.705
Waist circumference (cm) 3,953 99.4615.3 98.7614.7 98.6616.0 0.156
C-reactive protein (mg/l) 2,374 5.9168.3 5.9967.7 6.2969.2 0.695
Metabolic syndrome (%) 3,786 44.3 40.3 40.9 0.037
Note: Data are mean 6 SD for quantitative variables and percentages for
categorical variables. Sample sizes are the number of participants with
non-missing information for the respective variable out of 3,960 genotyped
individuals (2,690 CC, 1,134 CT,1 3 6TT). All measurements are from baseline with
the exceptions of 2 hr post-OGTT glucose and C-reactive protein, which were
only measured at the 4
th visit. P values given for association with rs780094 in
linearregressionforquantitativetraitsandlogistic regressionforqualitativetraits.
doi:10.1371/journal.pone.0011690.t004
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lower HOMA-B (p=0.011) and higher HDL cholesterol(p=0.022)
were also observed. The T allele showed significant association with
higher prevalence of the metabolic syndrome (p=10
26), which
disappeared when adjustment for triglycerides was performed. No
relationships with systolic blood pressure and waist circumference
were observed under either of the models.
Characteristics of black ARIC participants by genotype are listed
in Table 4. The T-allele of rs780094 was nominally associated only
with higher triglyceride levels (p=0.05) and lower HOMA-IR
(p=0.023) and metabolic syndrome prevalence (p=0.037) in
univariate models. In multivariable adjusted analyses, the T-allele
additionallyshowedassociationwithlowerinsulinlevels(p=0.002);
the relationship with metabolic syndrome became insignificant
(Table 5).
Over a mean follow-up period of 8 years, 935 out of 9,230 white
participants without diabetes at baseline developed diabetes.
Figure 1A shows the cumulative incidence of diabetes stratified
by rs780094 genotype. In Cox proportional hazards models,
relative hazards were significantly lower with each additional copy
of the T allele (model 1: HR 0.89; 95% CI, 0.81–0.98, p=0.014;
model 2: HR 0.85; 95% CI, 0.77–0.93, p=4.6610
24). Among
10,600 participants, 418 suffered a stroke (model 1: HR 0.94; 95%
CI, 0.82–1.08, p=0.363; model 2: HR 0.96; 95% CI, 0.83–1.11,
p=0.570) and 1,705 developed CHD (model 1: HR 0.97; 95%
CI, 0.91–1.04, p=0.422; model 2: HR 0.98; 95% CI, 0.91–1.05,
p=0.523) over a mean follow-up period of 15 years; rs780094 was
not significantly associated with either outcome.
Among black study participants, 478 of 2,626 without diabetes
at baseline developed diabetes over a mean follow-up period of
7 years. Figure 1B shows the cumulative incidence of diabetes
stratified by rs780094 genotype: TT carriers had lower incidence
of diabetes than CC carriers over the duration of follow-up, but the
difference was not statistically significant. A stroke was suffered by
273 of 3,513 participants over a mean follow-up period of 15
years, and 408 participants developed CHD over this time period.
rs780094 was not significantly associated with either outcome
([stroke: model 1: HR 0.97; 95% CI, 0.78–1.21, p=0.79; model 2:
HR 0.96; 95% CI, 0.77–1.120, p=0.75], [CHD (model 1: HR
1.10; 95% CI, 0.93–1.31, p=0.28; model 2: HR 1.08; 95% CI,
0.91–1.29, p=0.37]).
A set of sensitivity analyses was conducted using a sub-sample of
white participants without diabetes and who reported taking no
lipid-lowering medications at baseline (Table S1). The associations
of the rs780094 T-allele and most lipid and glycemic traits were
strengthened. In contrast to analyses conducted on the overall
sample, we observed an association of the T allele with higher
systolic blood pressure (model 1: p=0.016; model 2: p=0.002). As
multiple measurements of glucose, insulin, triglycerides, HDL,
waist circumference and blood pressure are available in the ARIC
Study, additional sensitivity analyses were conducted using mean
values of these variables. Results remained similar with the
exception of the association of the T allele with higher HDL
cholesterol levels, which clearly became stronger (Table S2).
Discussion
Using a large, population-based cohort, our study replicated all
previous associations of the GCKR rs780094 polymorphism with
metabolic traits, including fasting glucose, insulin, post-OGTT
Table 5. Adjusted Associations between rs780094 and Study Outcomes in Black Atherosclerosis Risk in Communities Study
Participants.
Model 1* Model 2*
Quantitative traits Effect/T allele ± SE P Effect/T allele ± SE P
Triglycerides (mmol/l) +0.0660.03 0.016 +0.0760.02 0.004
Fasting glucose (mg/dl) 20.8661.4 0.537 20.6861.3 0.609
Fasting insulin (pmol/l) 216.1865.6 0.004 216.5365.4 0.002
HOMA-IR 20.9360.4 0.030 21.0660.4 0.013
HOMA-B +4.99620.9 0.811 +3.43620.9 0.870
Waist circumference (cm) 20.6060.5 0.192 20.4660.5 0.301
HDL cholesterol (mg/dl) +0.5660.5 0.284 +0.8160.5 0.100
Systolic blood pressure (mmHg) 20.3560.6 0.584 20.3460.6 0.587
C-reactive protein (mg/l) +0.3060.3 0.353 +0.3260.3 0.314
2 hr post-OGTT glucose (mg/dl) +3.1962.9 0.277 +1.9461.8 0.279
Categorical traits OR/T allele (95% CI) P OR/T allele (95% CI) P
Diabetes mellitus 0.98 (0.83–1.16) 0.843 0.95 (0.80–1.13) 0.569
Metabolic syndrome 0.89 (0.79–1.01) 0.071 0.96 (0.83–1.10) 0.536
Incident events HR/T allele (95% CI) P HR/T allele (95% CI) P
Diabetes mellitus 0.91 (0.77–1.08) 0.284 0.94 (0.79–1.12) 0.494
Coronary heart disease 1.10 (0.93–1.31) 0.279 1.08 (0.91–1.29) 0.368
Stroke 0.97 (0.78–1.21) 0.791 0.96 (0.77–1.20) 0.750
*Note: Model 1 adjusted for age, sex, study center; model 2 adjusted for age, sex, study center, fasting glucose, fasting insulin, triglycerides. Metabolic syndrome was not
adjusted for glucose and triglycerides in model 2. HOMA-IR, HOMA-B, and DM not adjusted for fasting glucose and insulin in model 2. All cross-sectional associations
evaluated using baseline measurements (n=3,513, except for 2 hr post-OGTT glucose (n=1,450) and C-reactive protein (n=2,123), which were only measured at visit 4.
478 participants out of 2,626 developed DM over mean follow-up of 8 years; 408 out of 3,513 developed CHD and 273 out of 3,513 experienced a stroke over mean
follow-up of 15 years.
doi:10.1371/journal.pone.0011690.t005
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prevalence among white participants. In addition, we observed
associations of the rs780094 T-allele with decreased beta-cell
function as assessed by HOMA-B and increased HDL cholesterol
levels. The T-allele was nominally associated with increased
prevalence of the metabolic syndrome. Among a large sample of
African American participants, the variant was only marginally
associated with serum triglyceride and insulin levels and HOMA-
IR. Prospectively, among white participants the rs780094 T-allele
was significantly associated with lower incidence of diabetes over a
mean follow-up of 8 years, but not with incidence of CHD or
stroke over a mean follow-up of 15 years. All associations were
confirmed in sensitivity analyses using a subsample of participants
without diabetes and not taking lipid-lowering medication. The
observed associations with multiple metabolic traits therefore
implicate the rs780094 variant as an example of pleiotropy
emerging from GWAS, or may be indicative of a central
connection between hepatic pathways of glucose and lipid
metabolism.
This is one of the first and the largest study thus far investigating
the association of rs780094 (or rs1260326, a variant in high
linkage disequilibrium (LD)) and metabolic traits among African
Americans[17]. As our findings did not extend to participants who
self-identified as black, the intronic SNP rs780094 is likely not the
causal variant itself but rather in LD with such a variant in
European and Asian-ancestry populations but not African-
ancestry populations. The GCKR LD block contains a non-
synonymous coding SNP, rs1260326 (Pro446Leu). A previous
fine-mapping effort within the region in European-ancestry
individuals identified rs1260326 as the variant most strongly
associated with triglyceride levels[17]. In addition, a recent
functional study demonstrated that a Pro446Leu mutation in
rs1260326 resulted in attenuated fructose-6-phosphate enhance-
ment of GKRP activity in the liver [40]. rs1260326 is in strong LD
with rs780094 in the HapMap CEU (r
2=0.93) and CHB/JPT
(r
2=0.83) populations, but only moderate LD in the HapMap
YRI sample (r
2=0.43). In addition to differences in LD pattern,
we also had less power to detect significant associations in the
black study participants due to a smaller sample size and lesser
frequency of the T-allele as compared to the white study
participants. While the effect estimates for association with serum
triglycerides were of comparable size among white and black study
participants, the effect estimates for an association with most other
traits were smaller among African Americans.
As in past studies, we did not observe an association of rs780094
with incident CHD and stroke despite the association of rs780094
with a number of cardiovascular risk factors, possibly because of
the opposing effects of the SNP on the individual risk factors. The
T-allele is simultaneously associated with lower fasting glucose,
characteristic of a favorable CVD risk profile, and higher
triglyceride and uric acid levels, characteristic of an unfavorable
CVD risk profile. Alternatively, the small proportion of variance of
the individual glycemic and lipid traits explained by rs780094 (less
than 1% for all individual traits) may have contributed to the lack
of association with incident cardiovascular outcomes we observed.
Similarly, rs780094 is simultaneously associated with both
favorable and unfavorable components of the metabolic syn-
drome. The association of the T-allele with increased metabolic
syndrome prevalence in white participants could be explained by
the greater strength of the relationship with increased triglyceride
levels as compared to lower glucose levels. This notion is supported
by the fact that the association between the T allele and metabolic
syndrome prevalence disappeared upon further adjustment for
triglyceride concentrations.
GKRP is produced in molar excess over glucokinase in liver
hepatocytes. Under conditions of low glucose, GKRP allosterically
inhibits the phosphorylation of glucose to glucose-6-phosphate by
glucokinase; the combined glucokinase/GKRP complex is subse-
quently sequestered in the nucleus [10]. Experimental observa-
tions in mice suggest this inhibition also functions to protect
glucokinase against degradation by cytoplasmic proteases[41,42].
The underlying mechanism of action of the GCKR polymorphism
was proposed in a previous functional study, which observed that
the Pro446Leu mutation at rs1260326 resulted in attenuation of
fructose-6-phosphate enhancement of GKRP activity[43]. Under
this model, lower fasting glucose levels could occur as a result of
increased glycolytic flux due to lowered inhibition of glucokinase
by GKRP. Simultaneously, the body’s ability to respond to a
postprandial glucose surge is weakened because of a smaller pool
of reserve glucokinase. These expectations are in line with the
rs780094 T-allele’s opposing and simultaneous associations with
lower fasting and higher post-OGTT glucose levels. In addition,
we observed a trend towards an association of the T-allele with
decreased beta-cell function as assessed by HOMA-B, which
became more significant after further adjusting for triglyceride
levels. This association has not been observed in most other
studies[13,18], and may suggest an as-of-yet unknown function of
Figure 1. Cumulative incidence of diabetes stratified by
genotype among 9,356 white (panel A) and 2,626 black (panel
B) Atherosclerosis Risk in Communities participants over a
mean of 8 years of follow-up.
doi:10.1371/journal.pone.0011690.g001
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levels in comparison to GCK[40]. Another study in Han Chinese
found a similar association in the opposite direction[25]. In that
study, the minor allele of rs780094 was associated with increased
insulin levels, in contrast to the findings of most studies of GCKR
thus far[12,16,18].
The strengths of our study include the large size of the ARIC
Study, the inclusion of both white and African-American
individuals, the availability of a wide range of metabolic risk
factors, and the inclusion of prospective data on incident diabetes,
CHD and stroke. We also note the limitations of our study. First,
we examined only one SNP, rs780094, in the GCKR gene.
However, rs780094 has been replicated consistently and is in high
LD with a reportedly functional variant, rs1260326, in European-
ancestry populations. We chose a conventional significance
threshold of 0.05 to evaluate the association between one exposure
and several pre-specified outcomes; correction for multiple testing
would not have changed the conclusions for the highly significant
associations we observed. Second, baseline measurements for
OGTT and CRP were unavailable and we therefore used data
collected an average of 9 years later. However, there is no
evidence of a differential effect of rs780094 with respect to age,
and covariates were always taken from the same visit at which an
outcome was measured.
In conclusion, our study provides evidence of a common GCKR
variant associated with multiple metabolic traits including
glycemic and lipid traits and CRP levels in white ARIC Study
participants. Among black study participants, only the associations
with triglycerides, insulin and HOMA-IR were nominally
significant, suggesting that rs780094 of GCKR is not a causal
variant. The rs780094 T-allele was associated with lower diabetes
prevalence and incidence; it was not associated with incident CHD
or stroke.
Supporting Information
Table S1 Adjusted Associations between rs780094 and Study
Outcomes in 9,356 White Atherosclerosis Risk in Communities
Study Participants Without Diabetes and Not Taking Lipid-
Lowering Medications at Baseline. * Model 1 adjusted for age, sex,
study center; model 2 adjusted for age, sex, study center, fasting
glucose, fasting insulin, triglycerides. HOMA-IR, HOMA-B, and
DM not adjusted for fasting glucose and insulin in model 2. All
cross-sectional associations evaluated using baseline measurements
(n=9,356), except for 2 hr post-OGTT glucose (n=5,674) and C-
reactive protein (n=6,086), which were only measured at visit 4.
890 participants out of 8,917 developed DM over mean follow-up
of 8 years; 1,291 out of 9,356 developed CHD and 319 out of
9,356 experienced a stroke over mean follow-up of 15 years.
Found at: doi:10.1371/journal.pone.0011690.s001 (0.04 MB
DOC)
Table S2 Effect of using repeated measurements versus cross-
sectional measurements to evaluate the association between
rs780094 and different outcomes in 10,601 White Atherosclerosis
Risk in Communities Study Participants. Model 2 adjusted for age,
sex, study center, insulin, fasting glucose, triglycerides. The right-
hand side of the table presents results for mean values of insulin,
glucose, and triglycerides, and adjusting for mean levels of
covariates. Repeated measurements were available from ARIC
visits 1 and 4 for insulin, from ARIC visits 1, 2 and 4 for glucose,
and for ARIC visits 1, 2, 3, and 4 for triglycerides, waist
circumference, HDL cholesterol, and systolic blood pressure. *not
adjusted for fasting glucose and insulin.
Found at: doi:10.1371/journal.pone.0011690.s002 (0.04 MB
DOC)
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